| Miao Zhang,Zhaozhe Liu,Zhendong Zheng,Tao Han,Yaling Han,Min Song,Xiaodong Xie. Clinical observation of capecitabine monotherapy in elderly patients with advanced breast cancer. Oncol Transl Med, 2015, 1: 78-81. |
| Clinical observation of capecitabine monotherapy in elderly patients with advanced breast cancer |
| Received:November 19, 2014 Revised:April 01, 2015 |
| View Full Text View/Add Comment Download reader |
| KeyWord:capecitabine; elderly; advanced breast cancer; drug therapy |
| Author Name | Affiliation | E-mail | | Miao Zhang | Graduate school,Da Lian medical university,Da Lian,Liaoning | 125505866@qq.com | | Zhaozhe Liu | Oncology Department, General Hospital of Shenyang Military Region, Shenyang 110840, China | 125505866@qq.com | | Zhendong Zheng | Oncology Department, General Hospital of Shenyang Military Region, Shenyang 110840, China | 125505866@qq.com | | Tao Han | Oncology Department, General Hospital of Shenyang Military Region, Shenyang 110840, China | 125505866@qq.com | | Yaling Han | Oncology Department, General Hospital of Shenyang Military Region, Shenyang 110840, China | 125505866@qq.com | | Min Song | Oncology Department, General Hospital of Shenyang Military Region, Shenyang 110840, China | 13309882697@163.com | | Xiaodong Xie | Oncology Department, General Hospital of Shenyang Military Region, Shenyang 110840, China | 510503094@qq.com |
|
| Hits: 7031 |
| Download times: 7638 |
| Abstract: |
| Objective: The aim of the study was to evaluate the safety and efficacy of capecitabine mono-chemotherapy in elderly patients with advanced breast cancer.
Methods: The data from 36 cases of capecitabine monotherapy in elderly patients with advanced breast cancer were retrospectively analyzed. Oral administration of capecitabine 2000 mg/m2 twice daily (D1–14) for 21 days constituted a cycle. The effect of the disease and main adverse reactions were evaluated every 2 cycles.
Results: The data from 36 elderly patients were studied. The median number of chemotherapy cycles was 4. The total effective rate was 30.6% (11/36) and the disease control rate was 72.2% (26/36). The number of patients with clinical complete remission was 2, clinical partial response was 9, stable disease was 15, and progressive disease was 10. Where treatment was effective, the median time to progression was 6 months and the median overall survival was 9.5 months. The main adverse events were gastrointestinal reactions, bone marrow suppression, and oral mucositis; most of the reactions were grade 1 to 2. Grade 3 to 4 adverse reactions included granulocytopenia in 2 patients (12.5%) and hand-foot syndrome in 1 patient (6.7%).
Conclusion: Capecitabine monotherapy was effective in controlling disease progression, and adverse reactions were tolerated by elderly patients with advanced breast cancer. |
| Close |
|
|
|